BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine

BioNTech has axed a Phase 2 trial of its personalized mRNA cancer vaccine just a week after Moderna and Merck had breakout success for their own approach in a much different cancer setting. BioNTech said ...